ROXRO Announces FDA Approval of SPRIX(TM) - PR Newswire (press release) PDF Print
ROXRO Announces FDA Approval of SPRIX(TM)PR Newswire (press release)Renal risk – SPRIX is CONTRAINDICATED in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.ROXRO Announces FDA Approval of SPRIX(TM) Bradenton Herald all 6 news articles »

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.